Background: Oncology clinicians are now routinely provided with an estimated glomerular filtration rate on pathology reports whenever serum creatinine is requested. The utility of using this for the dose determination of renally excreted drugs compared with other existing methods is needed to inform practice. Conclusion: All bedside formulae provide similar levels of concordance in dosage selection for the renal excreted chemotherapy drugs when compared with the use of a direct measure of renal function.
introduction
The assessment of renal function in cancer patients is important in clinical practice. Over 50% of oncology patients have renal insufficiency (RI) and may require dose adjustment of anticancer treatments [1] . Practice guidelines have been formulated to assist in the management of these patients [2, 3] . However, challenges faced by clinicians include the assessment of the degree of RI.
Accurate measurement of glomerular filtrate rate (GFR) is possible but not routinely used due to invasive nature, time constraints, cost and availability [4, 5] . Consequently, bedside estimates are required to assess renal function. The most frequently applied approximation is serum creatinine (SCr) concentration, which alone is not appropriate for evaluating renal function [1, 2, 4, 5] . Various bedside formulae utilising SCr have been developed and adopted into practice [6, 7] . Two oncology derived formulae, the Wright and Martin formulae, are also used to varying degrees [8, 9] . Recently, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula has been recommended to replace other formulae in practice [10] .
Clinicians are now routinely provided with an estimated GFR (eGFR) through automated pathology reports calculated from SCr using the 4-variable Modification of Diet in Renal Disease (4v-MDRD) formula [11] . Oncology clinicians presented with this estimation require guidance on the applicability for use in dose calculation.
The aim was to determine the accuracy and impact of formula-based estimates of renal function on the dosage selection of renally cleared chemotherapy agents in an oncology patient population.
patients and materials
Consecutive cancer patients presenting to the Peter MacCallum Cancer Centre, Melbourne, Australia, for the measurement of GFR were recruited. Only patients with SCr concentration measured within 14 days of GFR measurement were included. Body surface area (BSA) [12] and body mass index (BMI) were calculated. Ethics approval for the conduct of this study was obtained.
GFR was determined by technetium 99m diethylene-triamine-penta acetic acid ([Tc   99m ]DTPA) clearance, as previously described [13] . GFR was expressed in ml/min. SCr was measured using an alkaline picrate-kinetic rate blanked, compensated method (Jaffe method; Roche Diagnostic Hitachi 912 reagent). SCr measurements were not standardised to isotope dilution mass spectrometry (IDMS).
Renal function estimates were calculated using the 4v-MDRD [7] , the CKD-EPI [10] , Cockcroft and Gault (CG) [6] , Wright [8] and Martin [9] formulae (see supplementary Table 1 , available at Annals of Oncology online). Actual body weight (ABW) and ideal body weight (IBW) were used in the CG formula. No adjustment for ethnicity was included. SCr concentration of <60 µmol/l were rounded to 60 µmol/l [14] .
Chemotherapy agents requiring dosage adjustment in renal impairment were selected from the Cancer Institute of New South Wales 'Cancer treatments online' protocols (see supplementary Box 1, available at Annals of Oncology online). Dose reductions were recommended in renal function dosing categories' (<30, 30-50 and >50 ml/min).
The simulated dose of carboplatin was determined using the Calvert formula and a targeted area under the concentration-time curve of 6 mg/ml min [15] . The above methods for estimates of renal function and measured GFR were used to calculate dose.
statistical analysis
Measured GFR was compared with calculated renal function. Accuracy of the formulae was assessed (mean percentage error) and mean absolute percentage error). Statistical analyses were carried out using the Excel (Microsoft Office Excel, 2002; Microsoft Corp., Redmond, WA, USA) and Stata version 12.0 (College Station, TX, USA).
assessment of concordance with renal function
The percentage of patients assigned to The National Kidney Foundation CKD categories [16] were calculated for measured GFR and renal function estimates (ml/min/1.73 m 2 ). Concordance was calculated and significance of differences was tested using the McNemar test and weighted kappa statistic.
assessment of concordance with chemotherapy dose determination
Concordance of the categories assigned using measured GFR were compared with the assignment category using renal function estimates. All estimates were expressed in ml/min. The 4v-MDRD and CKD-EPI were also expressed as ml/min/1.73 m 2 . Differences in concordance were tested using the McNemar test and weighted kappa statistic.
For carboplatin, concordance was calculated as the percentage of patients with the calculated dose being within ±20% of the dose determined from the Calvert formula using measured GFR. Differences in concordance were tested using the McNemar test.
results patient demographics
There were 455 patients included ( Table 1 ). The most frequent cancer diagnoses (supplementary Table 2 , available at Annals of Oncology online) were lung (29.7%), head and neck (16.9%) and gastrointestinal (9.7%) cancer; 443 patients (97.4%) were chemotherapy naive.
renal function
The mean measured GFR was 84.6 ± 32 ml/min. Table 1 includes the distribution of measured GFR, according to the CKD classification.
assessment of concordance of renal function Table 2 compares estimated and measured GFR (mGFR). Concordance with CKD GFR classification is detailed in Table 3 . The difference in concordance among equations were 
assessment of concordance with chemotherapy dose determination
Concordance for chemotherapy dosing is detailed in Table 4 . The Martin, Wright, 4v-MDRD and CKD-EPI equations (in ml/min) were all significantly more concordant than the CG and CG-I (P < 0.05). The concordance of 4v-MDRD, expressed in ml/min (89.0%), was significantly more concordant than 4v-MDRD, expressed in ml/min/1.73 m 2 (87.5%, P = 0.02). The concordance of the CKD-EPI, expressed in ml/min (89.5%), was significantly more concordant than CKD-EPI, expressed in ml/min/1.73 m 2 (87.5%, P = 0.04). Figure 1 provides comparisons of dosing concordance between measured and eGFR for chemotherapy dosing across the subgroups of age, gender and BMI.
For carboplatin, the proportion of patients with a concordant dose is presented in Table 4 . The Martin, Wright and CKD-EPI equations (in ml/min) were all significantly more concordant than the 4v-MDRD, CG and CG-IBW (P < 0.05). The carboplatin dose concordance of 4v-MDRD, expressed in ml/min (66.4%), was significantly more concordant than 4v-MDRD, expressed in ml/min/1.73 m 2 (56.9%, P < 0.001). The carboplatin dose concordance of the CKD-EPI, expressed in ml/min (71.4%), was significantly more concordant than CKD-EPI, expressed in ml/min/1.73 m 2 (60.9%, P < 0.001). There was no significant difference between 4v-MDRD (in ml/ min) and CG formulae (P = 0.315). discussion This is the first study in oncology patients to quantify the impact of using the 4v-MDRD and CKD-EPI formulae for calculating doses of renally excreted cytotoxic chemotherapy. This is important as the CKD-EPI equation has been proposed to replace the 4v-MDRD equation in clinical practice [10, 17] .
The key findings are that all the bedside formulae result in similar levels of concordance in dosage selection for the renal excreted chemotherapy drugs when compared with a direct measure of renal function. The CG formula with IBW was the least concordant. Our data do not demonstrate any significant clinical advantage for the oncology derived Martin, Wright or the CG formulae over the automatically reported eGFR, calculated from either the 4v-MDRD or the CKD-EPI formula.
There have been a number of studies examining various estimations of renal function in oncology patients; however, none have been carried out examining dosage selection across all the formulae with a direct measure of renal function [18] [19] [20] [21] [22] [23] .
Our data reaffirm that of others that there is no advantage of the CG formulae over the more recently derived formulae [24] . Our data also demonstrate that the substitution of IBW for ABW into the CG formula results in a significantly greater degree of imprecision.
All formulae resulted in a dose of carboplatin greater than ±20% of that targeted in over 20% of cases. All formulae significantly underdosed, with the Martin, Wright and CKD-EPI (ml/min) the least discordant. There have been no other published studies that have directly compared the suitability of the CKD-EPI, 4v-MDRD, CG formula and the two oncology formulae for calculating carboplatin doses. original articles
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The increasing use of IDMS measured SCr concentration in GFR dosing formulae may result in eGFR values that are 5% or more higher than that when non-IDMS methods are used. It has been reported that increased toxicity associated with carboplatin has been seen since the introduction of IDMS measured SCr. In view of the concerns regarding overestimating GFR when using IDMS measured SCr, capping eGFR at 125 ml/min has been recommended to reduce the risk of toxicity [25] . Our study was conducted using a non-IDMS method of measuring SCr, and hence the concordance between eGFR by the formulae and the measured GFR may be different. SCr measurements were not standardised to the IDMS method; however, the method utilised has been validated and shown to be accurate when compared with the IDMS method [26, 27] . Concordance between the formulae would not be expected to be different as the method of SCr measurement was the same for all formulae estimations.
All bedside formulae are based on SCr and need to be interpreted with the knowledge that factors affecting creatinine production and excretion will impact on the prediction of renal function, especially at extremes of muscle mass [3, 4, 10] . Our data demonstrate that there was poorer concordance in patients over 65 years of age for all formulae with the lowest concordance for the CG formula. There were only four patients aged over 85 years. Concordance improved with increasing BMI with the exception of the CG formula adjusted with IBW, which significantly underdosed obese patients (BMI >30 kg/m 2 ). There is growing evidence to demonstrate that empiric dose reductions for obese patients result in poorer clinical outcome [28, 29] and the use of the CG formula adjusted with IBW cannot be supported.
Our findings provide guidance to clinicians regarding the use of bedside estimates of renal function in the calculation of doses of chemotherapy. Automatically reported eGFR is at least equivalent to any of the other formula currently available. The eGFR is reported in ml/min/1.73 m 2 and our data show that this must be adjusted with BSA into ml/min when used in drug dosing. The use of eGFR will be incorporated into future drug dosing guidelines, product monographs and clinical studies and should be adopted into clinical practice, replacing other formulae [24, 30, 31] .
Our study fulfils criteria recommended for developing and validating GFR estimating equations [32] . However, there are some aspects of our study that require consideration. This study did not include a prospective dosing component or assessment of any clinical outcomes. Data involved only adult patients. The patients were from a diverse oncology population rather than having a single type of cancer. Renal function estimates were based on a single Scr concentration, and no assessment of variable renal function was undertaken; however, this was not an acutely unwell population and is unlikely to impact results. We did not assess the Chatelut formula for carboplatin dosing due to gender bias limitations [33] .
Clinicians, making decisions regarding dosing adjustment in organ dysfunction, are in the challenging position of having relatively imprecise measures available to define the degree of dysfunction, compounded by the lack of pharmacokinetic data to inform the impact of this on either potential toxicity or efficacy. Future research needs to focus on improved alternatives for estimating renal function and greater evaluation of the impact of renal impairment on drug handling.
conclusion
The key findings are that all the bedside formulae result in similar levels of accuracy in dosage selection for the renally excreted chemotherapy drugs. The CG formula with IBW was the least concordant. These data did not demonstrate any significant clinical advantage in dose determination for the oncology derived formulae, or the CG formula, over the automatically reported eGFR, calculated from the 4v-MDRD or the CKD-EPI formulae. 
